Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
Status:
Terminated
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786
for the treatment of Intermittent Explosive Disorder (IED).